Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 43 / 2026
- Best Stem Cell Center India: Advanced Regenerative Medicine for International PatientsIndia is emerging as a destination for international patients seeking stem cell therapy. Reputable centers focus on experienced specialists, personalized care, modern facilities, patient safety, transparency, and comprehensive international support.
- Robbins Geller Rudman & Dowd LLP1 MONTH CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 DeadlineRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September...
- CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-
- Agenus Inc.Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming MechanismLEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.
- Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical PrecancerNORTH BETHESDA, Md., August 28, 2026--Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines. With an Investigational New Drug application cleared by the FDA, Pinion is ready to begin clinical development for women with HPV-16-positive high-grade cervical precancer (CIN2/3).
- Aprea TherapeuticsAprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology ProgramsCompany Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
- Formosa Pharmaceuticals Inc.Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast CancersTSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. — Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application...
- BioLineRx Ltd.BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private PlacementBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive...
- HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered SimulationMemorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors...
- Minerva Neurosciences, IncMinerva Neurosciences to Participate in Two Upcoming Investor ConferencesMinerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.
- Samsung Biologics拟募资逾20亿美元，为收购PolyPeptide和业务扩张提供资金Samsung Biologics计划通过配股募资逾20亿美元，为计划中的对PolyPeptide Group的收购及其制造产能扩张提供资金。 这家隶属于三星集团（Samsung Group）的韩国生物类似药制造商周五表示，将以每股1，322，000韩元的价格发行约230万股新股，以筹集约3万亿韩元（相当于21.7亿美元）的资金。这些新股计划于11月上市。 Samsung Biologics表示，计划将所募资金中的约2.71万亿韩元用于收购瑞士合同开发与制造组织PolyPeptide。该公司预计这项于7月宣布的交易将在11月完成。 这家韩国公司表示，对PolyPeptide的收购交易有望扩大Samsung Biologics的产品组合，使其在抗体和抗体药物偶联物之外，进一步拓展至多肽疗法领域，从而帮助其满足全球对多样化疗法快速增长的需求。 与此同时，该公司表示，计划到2032年将其全球制造产能从目前的845，000升提高至约14